uniQure’s (QURE) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of uniQure (NASDAQ:QURE) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $25.00 target price on the biotechnology company’s stock.

QURE has been the topic of a number of other reports. Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 target price on shares of uniQure in a report on Wednesday. The Goldman Sachs Group decreased their target price on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday. Raymond James reaffirmed an “outperform” rating and issued a $20.00 target price on shares of uniQure in a research note on Thursday, October 10th. StockNews.com raised uniQure to a “sell” rating in a research note on Thursday, October 17th. Finally, Royal Bank of Canada lowered their price objective on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $17.00.

uniQure Stock Performance

NASDAQ QURE opened at $7.16 on Wednesday. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $11.35. The business has a fifty day moving average of $5.70 and a 200-day moving average of $5.79. The stock has a market cap of $348.69 million, a price-to-earnings ratio of -1.21 and a beta of 0.90.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Privium Fund Management B.V. boosted its holdings in uniQure by 16.3% in the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after acquiring an additional 104,500 shares during the last quarter. Atria Investments Inc acquired a new position in shares of uniQure in the 3rd quarter valued at about $53,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. abrdn plc grew its holdings in shares of uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the period. Finally, Ballentine Partners LLC acquired a new stake in uniQure during the 3rd quarter worth approximately $116,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.